Forgot how far this company has come in the last 4-5 months. Strong growth to date, strong growth expected. Well done management.
December 2017 Quarterly Activities Report
• Bod becomes one of the first ASX-listed companies to be granted a cannabis import licence – import of cannabis oils and raw materials expected during current quarter
• Significant quarter-on-quarter surge in revenue to $334,000 – an increase of 2.7x QoQ, additionally a net R&D tax rebate of $246,000 was received during the quarter
• Manufacturing and commercialisation agreement with iX Biopharma for ‘trial ready’ cannabis wafer signed – production progressing well at Australian facilities
• Phase I Clinical Trial fast tracked through revised study – set to commence near term • Proprietary hemp honey product being developed through HOA with Manuka Pharma – sales to be generated through Bod’s distribution channels first half CY2018
• Formulation work on cannabis-based cosmetic products initiated – range of topical treatments to be released during CY2018
• Bod continues to explore opportunities to broaden product range and channels to market – further growth to be realised across the current quarter
BDA Price at posting:
54.0¢ Sentiment: Buy Disclosure: Held
